RecruitingNCT06726811

Droperidol and QTc Interval Changes in ED Patients

Low-Dose Droperidol and Its Association with QTc Interval Changes in Emergency Department Patients


Sponsor

CHRISTUS Health

Enrollment

500 participants

Start Date

Oct 17, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Objectives To assess the association of low-dose Droperidol administration in the emergency department with changes in the QTc interval. Hypothesis Our study is designed to test the null hypothesis that there will be no clinically significant change in QTc interval after administration of 2.5mg of IV Droperidol during an emergency department visit.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • ED patients ages 18 years or older in a cardiovascular-monitored bed who have both an ECG and a 2.5 mg dose of IV droperidol ordered by their treating physician will be eligible for inclusion.

Exclusion Criteria3

  • Refusal to provide consent.
  • Administration of droperidol before the first ECG is performed.
  • Inability to complete the consent form and questionnaire due to clinical instability, severe pain, or disorientation as determined by a study physician.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDroperidol injection

2.5 mg


Locations(1)

CHRISTUS Spohn Hospital Corpus Christi-Shoreline

Corpus Christi, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06726811


Related Trials